Property:Query string

"Query string" is a predefined property that describes the conditions of the query as a string and is provided by Semantic MediaWiki. This property is pre-deployed (also known as special property) and comes with additional administrative privileges but can be used just like any other user-defined property.

Usage541

previous 202050100250500next 20

Filter<p>The <a rel="nofollow" class="external text" href="https://www.semantic-mediawiki.org/wiki/Help:Property_page/Filter">search filter</a> allows the inclusion of <a rel="nofollow" class="external text" href="https://www.semantic-mediawiki.org/wiki/Help:Query_expressions">query expressions</a> such as <code>~</code> or <code>!</code>. The selected <a rel="nofollow" class="external text" href="https://www.semantic-mediawiki.org/wiki/Query_engine">query engine</a> might also support case insensitive matching or other short expressions like:</p><ul><li><code>in:</code> result should include the term, e.g. '<code>in:Foo</code>'</li></ul><ul><li><code>not:</code> result should to not include the term, e.g. '<code>not:Bar</code>'</li></ul>

Showing 20 pages using this property.

U

USA 45 CFR Part 160 09-Apr-2025 +

[[Reference:+]] [[HasDocument::Document:USA 45 CFR Part 160 09-Apr-2025]]

USA 45 CFR Part 46 09-Apr-2025 +

[[Reference:+]] [[HasDocument::Document:USA 45 CFR Part 46 09-Apr-2025]]

USA Acceptance of Clinical Data to Support Medical Device Applications and Submissions Frequently Asked Questions - Guidance for Industry and Food and Drug Administration Staff 21-Feb-2018 +

[[Reference:+]] [[HasDocument::Document:USA Acceptance of Clinical Data to Support Medical Device Applications and Submissions Frequently Asked Questions - Guidance for Industry and Food and Drug Administration Staff 21-Feb-2018]]

USA CTCAE - Common Terminology Criteria for Adverse Events v5.0 (2017) +

[[Reference:+]] [[HasDocument::Document:USA CTCAE - Common Terminology Criteria for Adverse Events v5.0 (2017)]]

USA Expedited Review: Categories of Research that may be Reviewed Through an Expedited Review Procedure 1998 +

[[Reference:+]] [[HasDocument::Document:USA Expedited Review: Categories of Research that may be Reviewed Through an Expedited Review Procedure 1998]]

USA FD&C Act - Federal Food, Drug, and Cosmetic Act 30-Sep-2023 +

[[Reference:+]] [[HasDocument::Document:USA FD&C Act - Federal Food, Drug, and Cosmetic Act 30-Sep-2023]]

USA FDA - E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1): Guidance for Industry March 2018 +

[[Reference:+]] [[HasDocument::Document:USA FDA - E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1): Guidance for Industry March 2018]]

USA FDA - HUMAN DRUG CGMP NOTES Volume 8, Number 3 +

[[Reference:+]] [[HasDocument::Document:USA FDA - HUMAN DRUG CGMP NOTES Volume 8, Number 3]]

USA FDA Guidance for Clinical Investigators, Sponsors, and IRBs Adverse Event Reporting to IRBs — Improving Human Subject Protection Jan-2009 +

[[Reference:+]] [[HasDocument::Document:USA FDA Guidance for Clinical Investigators, Sponsors, and IRBs Adverse Event Reporting to IRBs â€” Improving Human Subject Protection Jan-2009]]

USA FDA Guidance for Industry - Computerized Systems Used in Clinical Investigations May-2007 +

[[Reference:+]] [[HasDocument::Document:USA FDA Guidance for Industry - Computerized Systems Used in Clinical Investigations May-2007]]

USA FDA Guidance for Industry - Computerized Systems Used in Clinical Trials 13-Apr-2015 +

[[Reference:+]] [[HasDocument::Document:USA FDA Guidance for Industry - Computerized Systems Used in Clinical Trials 13-Apr-2015]]

USA FDA Guidance for Industry - Conduct of Clinical Trials of Medical Products During the COVID-19 Public Health Emergency Mar-2020 +

[[Reference:+]] [[HasDocument::Document:USA FDA Guidance for Industry - Conduct of Clinical Trials of Medical Products During the COVID-19 Public Health Emergency Mar-2020]]

USA FDA Guidance for Industry - Electronic Source Data in Clinical Investigations Sep-2013 +

[[Reference:+]] [[HasDocument::Document:USA FDA Guidance for Industry - Electronic Source Data in Clinical Investigations Sep-2013]]

USA FDA Guidance for Industry - Oversight of Clinical Investigations — A Risk-Based Approach to Monitoring Aug-2013 +

[[Reference:+]] [[HasDocument::Document:USA FDA Guidance for Industry - Oversight of Clinical Investigations â€” A Risk-Based Approach to Monitoring Aug-2013]]

USA FDA Guidance for Industry Investigator Responsibilities — Protecting the Rights, Safety, and Welfare of Study Subjects Oct-2009 +

[[Reference:+]] [[HasDocument::Document:USA FDA Guidance for Industry Investigator Responsibilities â€” Protecting the Rights, Safety, and Welfare of Study Subjects Oct-2009]]

USA FDA INFORMATION SHEET - Recruiting Study Subjects, Guidance for Institutional Review Boards and Clinical Investigators Jan-1998 +

[[Reference:+]] [[HasDocument::Document:USA FDA INFORMATION SHEET - Recruiting Study Subjects, Guidance for Institutional Review Boards and Clinical Investigators Jan-1998]]

USA NIH - Glossary 27-May-2025 +

[[Reference:+]] [[HasDocument::Document:USA NIH - Glossary 27-May-2025]]

USA FDA Information - Observations and citations 20-Mar-2024 +

[[Reference:+]] [[HasDocument::Document:USA FDA Information - Observations and citations 20-Mar-2024]]

USA Informed Consent - FDA Guidance for IRBs, Clinical Investigators, and Sponsors Aug-2023 +

[[Reference:+]] [[HasDocument::Document:USA Informed Consent - FDA Guidance for IRBs, Clinical Investigators, and Sponsors Aug-2023]]

USA NCI GUIDELINES FOR INVESTIGATORS: ADVERSE EVENT REPORTING REQUIREMENTS FOR DCTD (CTEP AND CIP) INDs AND IDEs 30-Aug-2024 +

[[Reference:+]] [[HasDocument::Document:USA NCI GUIDELINES FOR INVESTIGATORS: ADVERSE EVENT REPORTING REQUIREMENTS FOR DCTD (CTEP AND CIP) INDs AND IDEs 30-Aug-2024]]